Physician profile
Brynn E Mona
NPI 1891410056
$1,765.29
in general payments reported to CMS, 2019-2025
25 companies · $955 in 2025
The $955 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $227 · 2024: $447 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $205.55 | 2022-2025 | Provenge |
| Sumitomo Pharma America, INC. | $176.12 | 2023-2025 | Gemtesa, Orgovyx |
| Novartis Pharmaceuticals Corporation | $146.46 | 2022-2025 | |
| Astellas Pharma US INC | $139.34 | 2025 | Xtandi |
| Procept Biorobotics Corporation | $135.20 | 2024 | Aquabeam System |
| Axonics, INC. | $133.59 | 2024 | Axonics |
| Teleflex LLC | $118.84 | 2022-2025 | Urolift |
| Abbvie INC. | $99.25 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $94.38 | 2023 | Pylarify |
| Endo USA, INC. | $83.71 | 2025 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $55.23 | 2025 | Lynparza, Keytruda |
| Endo Pharmaceuticals INC. | $43.84 | 2022-2023 | Aveed, Xiaflex, Edex |
| Ferring Pharmaceuticals INC. | $38.32 | 2025 | Adstiladrin |
| Bluewind Medical | $33.70 | 2024 | Revi |
| Sun Pharmaceutical Industries INC. | $32.43 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.13 | 2025 | Axonics |
| Urogen Pharma, INC. | $28.98 | 2025 | |
| Valencia Technologies Corporation | $26.96 | 2025 | Ecoin Device Kit |
| Tolmar, INC. | $25.73 | 2025 | Eligard |
| Astrazeneca Pharmaceuticals LP | $24.59 | 2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $23.02 | 2024 | |
| Myriad Genetic Laboratories, INC. | $22.00 | 2023 | Prolaris |
| Urovant Sciences INC | $16.75 | 2022 | |
| Sagent Pharmaceuticals | $15.47 | 2025 | Glydo |
| Tempus Ai, INC | $13.70 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brynn Mona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.